Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

Researchers use cryo-EM and optical tweezers to investigate how an antiviral interacts with the herpes simplex virus.

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

All organisms — from fungi to mammals — have the capacity to evolve and adapt to their environments. But viruses are master shapeshifters with an ability to mutate greater than any other organism. As ...

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership ...